On­col­o­gists want more treat­ment op­tions for ad­vanced lung can­cer pa­tients, new sur­vey says

On­col­o­gists are en­cour­aged by the num­ber of im­munother­a­pies to treat non-small cell lung can­cer, but they still want more op­tions, es­pe­cial­ly for ad­vanced cas­es, ac­cord­ing to a new Har­ris Poll sur­vey com­mis­sioned by Re­gen­eron and the Can­cer Re­search In­sti­tute.

The over­whelm­ing ma­jor­i­ty of ad­vanced NSCLC pa­tients have used im­munother­a­py as a first-line (97%) or sec­ond-line (86%) treat­ment, ac­cord­ing to the 250 on­col­o­gists sur­veyed, but 30% of those physi­cians say there’s still room for more op­tions. Few­er than one in five on­col­o­gists rat­ed the cur­rent op­tions as “ex­cel­lent.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER